SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSMC is trending as investors digest record-breaking monthly revenue results and high-level expectations for upcoming earnings amid a broader pullback in the semiconductor sector. Community discussions are centered on the company's aggressive capital expenditure plans, ongoing AI infrastructure demand, and potential geopolitical risks influencing volatility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is facing intense volatility as investors debate the sustainability of AI-driven memory demand, with community discourse heavily influenced by reports of semiconductor supply constraints and ongoing debates over structural versus cyclical valuation. While some participants express frustration over price swings and external market pressures from Asian exchanges, many remain bullish on the long-term potential of the AI supercycle, actively discussing price targets, potential short squeezes, and the impact of institutional accumulation.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk (SNDK) is experiencing intense volatility, driven by a broad sell-off across semiconductor and memory stocks as investors re-evaluate the sustainability of AI infrastructure spending. Community discussions are split between those viewing the pullback as a buying opportunity based on long-term data center demand and those warning of a cyclical bubble or potential manipulation by market makers.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

ATAI is experiencing heightened volatility and trading interest following reports that Eli Lilly is in advanced talks to acquire the psychedelic drug developer. Community sentiment is divided between excitement over a potential premium-priced buyout and skepticism regarding the deal's confirmation, while investors closely watch for official filings and signs of a competitive bidding war.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is facing intense community debate as investors weigh strong defense contract wins, such as the latest Navy and Marine Corps purchase orders, against concerns over share dilution and overall space sector volatility. While many shareholders remain bullish on the company's long-term potential as a critical infrastructure provider, the stock's price action continues to be heavily influenced by broader sector-wide selling pressure and skepticism from short-term traders.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing intense volatility as investors weigh the semiconductor sector's high AI infrastructure demand against growing concerns over memory chip supply gluts and regional geopolitical tensions. The community remains deeply divided, with some traders aggressively buying the dip on strong earnings expectations while others warn of a broader AI bubble bursting amidst rising volatility and macro uncertainty.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is experiencing heightened volatility as investors grapple with a new statewide moratorium on data center construction in New York, sparking intense debate over whether existing permits insulate the company from the mandate. While the community remains deeply divided between long-term bulls highlighting secured power assets and massive hyperscaler contracts, and shorts citing technical weakness and management's handling of the stock, market participants are closely watching how this regulatory pressure interacts with the companys ongoing infrastructure buildout.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate its transition toward agentic AI orchestration, with the community sharply divided between bulls citing massive short interest and strong fundamentals as squeeze triggers, and skeptics wary of persistent price stagnation. The stock is seeing heightened volatility and elevated trading volume as market participants watch for a potential breakout from its current accumulation structure.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is gaining significant momentum as investors anticipate imminent Phase 3 durability data, which serves as a critical catalyst for the company's rolling NDA submission and potential commercialization. Community discourse is heavily focused on the stock's status as a first-mover in the psychedelics sector and the broader validation of the industry following favorable regulatory signals and growing large-cap pharmaceutical interest.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors digest reports of potential M&A activity involving the psychedelic drugmaker Atai Life Sciences, while the stock continues to benefit from strong momentum in its blockbuster GLP-1 weight-loss and diabetes treatments. The community is actively debating the implications of this expansion into mental health therapies, closely monitoring the scaling of production, and analyzing how the broader healthcare sector's rotation is sustaining the company's valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the dosing of the first two patients in an investigator-sponsored Phase 2 trial evaluating DM199...

DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) regarding the need for additional nonclinical reproductive toxicity data to support continued development...

DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the Company will present at the 2026 Jefferies Global Healthcare Conference being held...

DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and fetal growth restriction, today announced that enrollment in its pivotal Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) in...

DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke...

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic...

DiaMedica Therapeutics (DMAC) Expected to Announce Quarterly Earnings on Wednesday

DiaMedica Therapeutics (NASDAQ:DMAC) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-diamedica-therapeutics-inc-stock...

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Rating of "Moderate Buy" from Brokerages

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the company, MarketBeat.com reports. One...

DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference

DiaMedica Therapeutics (NASDAQ:DMAC) President and CEO Rick Pauls outlined the company's development programs for its lead candidate, DM199, during a presentation at the RedChip Biotech Investor...

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction, and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases.

DiaMedica Therapeutics Inc

Bearish Sentiment

$100+

$80 - $99.99

$70 - $79.99

$60 - $69.99

Stripe and private equity firm Advent International just submitted a joint takeover offer for PayPal ($PYPL) at $60.50 per share, valuing the company at more than $53 billion - a roughly 28% premium to Tuesday's close. What do you think PayPal is really worth? Cast your vote and explain your reasoning in the comments.

What should PayPal ($PYPL) be worth in a takeover deal?

Current Price	$7.64
Prev Close	$7.43
Open	$7.41
Dividend Yield	0.00%
50-Day Moving Average	$6.36
Beta	1.20
Avg. Volume	232,139.46
PE Ratio	-10.84

52-Week High	$10.42
52-Week Low	$3.65
Market Capitalization	$400.35M
EPS (Annual)	-$0.6974
Price to Book	8.72
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

DMACDiaMedica Therapeutics Inc

Latest DMAC News